Evidence supporting the use of: Phytocannabinoid (unspecified)
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Phytocannabinoids—primarily cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)—have been investigated for their potential to alleviate symptoms of Parkinson's Disease (PD). The rationale stems from the modulation of the endocannabinoid system, which is implicated in motor control and neuroprotection. Several small clinical trials and observational studies have evaluated the effects of cannabinoids on PD symptoms such as tremor, rigidity, bradykinesia, and non-motor symptoms like sleep disturbances and psychosis.

Results to date are mixed. Some studies report minor improvements in quality of life, sleep, or reduction in dyskinesias (involuntary movements), while others find no significant effect on primary motor symptoms. The evidence base is limited by small sample sizes, lack of standardized formulations or dosing, and short study durations. Systematic reviews and meta-analyses (e.g., Kluger et al., 2021, JAMA Neurology; Ferreira et al., 2020, Movement Disorders) consistently conclude that there is insufficient high-quality evidence to support routine use, though research remains ongoing. Safety profiles are generally acceptable but may include sedation, cognitive changes, or psychosis, particularly with THC.

In summary, phytocannabinoids are being scientifically investigated for PD, but the current evidence supporting their use is weak (rated 2/5), and major neurology guidelines do not recommend them as standard treatment. Their use is thus justified by preliminary scientific research rather than tradition or robust clinical evidence.

More about Phytocannabinoid (unspecified)
More about Parkinson's Disease

Products containing Phytocannabinoid (unspecified)

We currently have no products on Vitabase that contain this ingredient.